Everolimus in pituitary tumor: a review of preclinical and clinical evidence
Although pituitary tumors (PTs) are mostly benign, some PTs are characterized by low surgical resection rates, high recurrence rates, and poor response to conventional treatments and profoundly affect patients’ quality of life. Everolimus (EVE) is the only FDA-approved mTOR inhibitor, which can be u...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1456922/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256044540821504 |
|---|---|
| author | Zihong Yao Zihong Yao Hui Chen |
| author_facet | Zihong Yao Zihong Yao Hui Chen |
| author_sort | Zihong Yao |
| collection | DOAJ |
| description | Although pituitary tumors (PTs) are mostly benign, some PTs are characterized by low surgical resection rates, high recurrence rates, and poor response to conventional treatments and profoundly affect patients’ quality of life. Everolimus (EVE) is the only FDA-approved mTOR inhibitor, which can be used for oral treatment. It effectively inhibits tumor cell proliferation and angiogenesis. It has been administered for various neuroendocrine tumors of the digestive tract, lungs, and pancreas. EVE not only suppresses the growth and proliferation of APT cells but also enhances their sensitivity to radiotherapy and chemotherapy. This review introduces the role of the PI3K/AKT/mTOR pathway in the development of APTs, comprehensively explores the current status of preclinical and clinical research of EVE in APTs, and discusses the blood-brain barrier permeability and safety of EVE. |
| format | Article |
| id | doaj-art-959083a10b1b474c8a3bdfb5ab7e37b4 |
| institution | OA Journals |
| issn | 1664-2392 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-959083a10b1b474c8a3bdfb5ab7e37b42025-08-20T01:56:44ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-12-011510.3389/fendo.2024.14569221456922Everolimus in pituitary tumor: a review of preclinical and clinical evidenceZihong Yao0Zihong Yao1Hui Chen2The Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of Endocrinology and Metabolism, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaDepartment of Endocrinology and Metabolism, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaAlthough pituitary tumors (PTs) are mostly benign, some PTs are characterized by low surgical resection rates, high recurrence rates, and poor response to conventional treatments and profoundly affect patients’ quality of life. Everolimus (EVE) is the only FDA-approved mTOR inhibitor, which can be used for oral treatment. It effectively inhibits tumor cell proliferation and angiogenesis. It has been administered for various neuroendocrine tumors of the digestive tract, lungs, and pancreas. EVE not only suppresses the growth and proliferation of APT cells but also enhances their sensitivity to radiotherapy and chemotherapy. This review introduces the role of the PI3K/AKT/mTOR pathway in the development of APTs, comprehensively explores the current status of preclinical and clinical research of EVE in APTs, and discusses the blood-brain barrier permeability and safety of EVE.https://www.frontiersin.org/articles/10.3389/fendo.2024.1456922/fullEverolimuspituitary tumorPI3K/AKT/mTORblood-brain barriersafety |
| spellingShingle | Zihong Yao Zihong Yao Hui Chen Everolimus in pituitary tumor: a review of preclinical and clinical evidence Frontiers in Endocrinology Everolimus pituitary tumor PI3K/AKT/mTOR blood-brain barrier safety |
| title | Everolimus in pituitary tumor: a review of preclinical and clinical evidence |
| title_full | Everolimus in pituitary tumor: a review of preclinical and clinical evidence |
| title_fullStr | Everolimus in pituitary tumor: a review of preclinical and clinical evidence |
| title_full_unstemmed | Everolimus in pituitary tumor: a review of preclinical and clinical evidence |
| title_short | Everolimus in pituitary tumor: a review of preclinical and clinical evidence |
| title_sort | everolimus in pituitary tumor a review of preclinical and clinical evidence |
| topic | Everolimus pituitary tumor PI3K/AKT/mTOR blood-brain barrier safety |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1456922/full |
| work_keys_str_mv | AT zihongyao everolimusinpituitarytumorareviewofpreclinicalandclinicalevidence AT zihongyao everolimusinpituitarytumorareviewofpreclinicalandclinicalevidence AT huichen everolimusinpituitarytumorareviewofpreclinicalandclinicalevidence |